Related Experiment Videos
Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect
1University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh, Pennsylvania 15213, USA.
Abstract:
Endostatin is a potent and specific antiangiogenic protein capable of inhibiting the growth of murine and xenotransplanted human tumors. Thus far, however, recombinant endostatin prepared from Escherichia coli is insoluble after purification and therefore inappropriate for clinical settings. A soluble form of endostatin is available from a yeast system with relatively low yield and high cost, which has made it difficult to produce endostatin in quantities sufficient for extensive clinical evaluation. In this study, we developed a protocol to generate soluble recombinant murine endostatin from E. coli at a yield of 150 mg/liter-culture and 99% purity. The in vivo antiangiogenic and antitumor activities of the soluble recombinant endostatin are equally as potent as those of the previously published insoluble form. A similar protocol may be used to produce soluble human endostatin.
Insights
Researchers developed a method to produce soluble endostatin from E. coli. This breakthrough enables large-scale, cost-effective production of this potent anti-cancer protein for clinical use.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Endostatin is a potent antiangiogenic protein inhibiting tumor growth.
- Current recombinant endostatin production methods face challenges with solubility, yield, and cost.
- Existing methods limit the clinical evaluation of endostatin.
Purpose of the Study:
- To develop a scalable and cost-effective protocol for producing soluble recombinant murine endostatin from Escherichia coli.
- To assess the in vivo antiangiogenic and antitumor activities of the newly developed soluble endostatin.
Main Methods:
- Engineered a protocol for recombinant murine endostatin expression in E. coli.
- Purified the recombinant endostatin to achieve high purity.
- Evaluated the biological activity of the soluble endostatin in vivo.
Main Results:
- Achieved a high yield of 150 mg/liter-culture with 99% purity for soluble recombinant murine endostatin.
- The soluble endostatin demonstrated potent in vivo antiangiogenic and antitumor activities, comparable to the insoluble form.
- The developed protocol shows potential for producing soluble human endostatin.
Conclusions:
- A novel, efficient protocol for producing soluble recombinant endostatin from E. coli has been established.
- This method overcomes previous limitations, enabling sufficient quantities for clinical evaluation.
- The findings pave the way for the broader clinical application of endostatin in cancer therapy.